Dr. Julie Bergeron
Claim this profileCIUSSSEMTL-Hopital Maisonneuve-Rosemont
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
3 reported clinical trials
13 drugs studied
Affiliated Hospitals
Clinical Trials Julie Bergeron is currently running
Screening Tool
for Myeloid Cancer
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).
Recruiting0 awards Phase 21 criteria
Combination Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the growth of cancer cells. Daunorubicin is a drug that blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Azacitidine is a drug that interacts with DNA to activate tumor-suppressing genes, resulting in an anti-tumor effect. Adding venetoclax to cytarabine and daunorubicin, and adding venetoclax to azacitidine, may work better than the usual treatment of cytarabine with daunorubicin alone. To decide if they are better, the study doctors are looking to see if venetoclax increases the rate of elimination of AML in participants by 20% or more compared to the usual approach.
Recruiting1 award Phase 26 criteria
More about Julie Bergeron
Clinical Trial Related1 year of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Julie Bergeron has experience with
- Azacitidine
- Cytarabine
- Daunorubicin Hydrochloride
- Venetoclax
- Imatinib
- Ponatinib
Breakdown of trials Julie Bergeron has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Julie Bergeron specialize in?
Julie Bergeron focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved treating patients, or patients who are undergoing treatment.
Is Julie Bergeron currently recruiting for clinical trials?
Yes, Julie Bergeron is currently recruiting for 2 clinical trials in Montreal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Julie Bergeron has studied deeply?
Yes, Julie Bergeron has studied treatments such as Azacitidine, Cytarabine, Daunorubicin Hydrochloride.
What is the best way to schedule an appointment with Julie Bergeron?
Apply for one of the trials that Julie Bergeron is conducting.
What is the office address of Julie Bergeron?
The office of Julie Bergeron is located at: CIUSSSEMTL-Hopital Maisonneuve-Rosemont, Montreal, Quebec H1T 2M4 Canada. This is the address for their practice at the CIUSSSEMTL-Hopital Maisonneuve-Rosemont.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.